查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1279656

2022-2029年全球微生物组治疗剂市场规模研究与预测，按类型（FMT、微生物组药物）、按应用（艰难梭菌、克罗恩病、炎症性肠病、糖尿病、其他）和区域分析。

Global Microbiome Therapeutics Market Size study & Forecast, by Type (FMT, Microbiome Drugs), By Application (C. difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others) and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2021年，全球微生物组治疗市场的价值约为921.5亿美元，预计在2022-2029年的预测期内将以超过35.32%的健康增长率增长。微生物组治疗旨在通过应用本地或合成细菌、抗生素、噬菌体和细菌素进行加法、减法或调节性治疗，对肠道微生物组进行改造。由于各种因素，包括在微生物组治疗领域的研发、产品开发和投资组合扩展方面的战略合作的增加，市场正在扩大。大多数正在开发的治疗药物仍处于早期阶段，通常在第一阶段和第二阶段之间。在这23种药物中，超过13种药物正在进行消化道适应症的研究，其中大部分集中在溃疡性结肠炎。例如，Seres Therapeutics公司在2021年披露了SER-109的3期ECOSPOR III研究的试验结果。该公司计划在2023年上半年推出该管线药物，作为复发性艰难梭菌感染的口服治疗药物。与安慰剂相比，SER-109与抗菌素抗性基因的减少有关。另外，2022年1月，哈德逊研究所和BiomeBank之间建立了为期4年的微生物药物开发和发现的伙伴关系。

随着目标疾病越来越普遍，对微生物组疗法的需求也在上升。微生物组研究的发展预计将猎取更有效的感染和其他疾病的治疗方法，改善医学治疗的效果。公司正在降低其商品的成本，使更多的人能够获得最先进的医疗服务，一些国家的管理当局正在改变其战略，以支持采用基于微生物组的治疗。因此，这为市场供应商提供了有利可图的增长机会，以增加他们的市场份额。微生物组治疗的高成本和产品的复杂性带来的严格监管规则是限制市场扩张的两个主要问题。

全球微生物组治疗法市场研究考虑的主要地区包括亚太、北美、欧洲、拉丁美洲和世界其他地区。2021年，北美拥有最大的市场份额，主导了该行业。该地区的主导地位主要是由于其完善的研究能力，以创造创新的治疗方法，以及其不断扩大的目标人群。另外，像加拿大微生物组计划（CMI）这样的倡议在加拿大无处不在，使其更容易与合作伙伴和利益相关者合作。这使得集中研究力量创建微生物药物成为可能。例如，Biocodex微生物群基金会在2021年7月发布了一项呼吁，要求在加拿大提交总额超过26,000美元的微生物群研究资金。这些激励措施预计将刺激新的市场创新。据预测，在预测期内，亚太地区将大幅增长，原因是老年病和目标人群不断增加，生物仿制药开发的合作数量增加，主要参与者的地理扩张，以及政府和非营利组织在市场空间的积极参与等因素。

该研究的目的是确定近年来不同领域和国家的市场规模，并预测未来几年的价值。该报告旨在将研究涉及的国家内的行业的质量和数量方面都纳入其中。

该报告还提供了关于关键方面的详细信息，如驱动因素和挑战，这将确定市场的未来增长。此外，它还纳入了微观市场的潜在机会，供利益相关者投资，并详细分析了竞争格局和主要参与者的产品。.

目录

第一章：执行摘要

  • 市场简介
  • 2019-2029年全球和细分市场的估计和预测
    • 2019-2029年，按地区分類的微生物组治疗剂市场
    • 2019-2029年，按类型分類的微生物组治疗剂市场
    • 2019-2029年，按应用分類的微生物组治疗剂市场
  • 主要趋势
  • 估算方法
  • 研究假设

第二章：全球微生物组治疗剂市场的定义和范围

  • 本研究的目的
  • 市场定义和范围
    • 研究的范围
    • 行业演变
  • 研究考虑的年份
  • 货币兑换率

第三章：全球微生物组治疗学市场动态

  • 微生物组治疗剂市场影响分析（2019-2029年）
    • 市场驱动力
      • 越来越多的微生物组治疗剂的战略合作进行研发
      • 目标疾病的发病率增加。
    • 市场挑战
      • 微生物组治疗剂的高成本
    • 市场机会
      • 配方的进步

第四章：全球微生物组治疗剂市场行业分析

  • 波特五力模型
    • 供应商的讨价还价能力
    • 买方的讨价还价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争性的竞争
  • 波特五力模型的未来方法（2019-2029年）
  • PEST分析
    • 政治因素
    • 经济
    • 社会
    • 技术
  • 投资采用模式
  • 分析师建议和结论
  • 最佳投资机会
  • 最佳策略

第五章：风险评估：COVID-19的影响

  • 评估COVID-19对行业的整体影响
  • COVID-19前和COVID-19后的市场情况

第六章：全球微生物组治疗剂市场，按类型划分

  • 市场简介
  • 按类型分類的全球微生物组治疗剂市场，性能-潜力分析
  • 2019-2029年全球微生物组治疗剂市场按类型的估计和预测
  • 微生物组治疗剂市场，細項分析
    • FMT
    • 微生物组药物

第7章 ：全球微生物组治疗剂市场，按应用分类

  • 市场简介
  • 全球微生物组治疗剂市场，按应用，性能 - 潜力分析
  • 2019-2029年全球微生物组治疗剂市场按应用估计和预测的情况
  • 微生物组治疗剂市场，細項分析
    • 艰难梭菌
    • 克罗恩病
    • 炎症性肠病
    • 糖尿病
    • 其他疾病

第八章：全球微生物组治疗剂市场，区域分析

  • 微生物组治疗剂市场，区域市场简介
  • 北美洲
    • 美国
      • 类型细分估计和预测，2019-2029年
      • 应用分类估计和预测，2019-2029年
    • 加拿大
  • 欧洲微生物组治疗剂市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区微生物组治疗药物市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲微生物组治疗剂市场概况
    • 巴西
    • 墨西哥
  • 世界其他地区

第九章：竞争情报

  • 顶级市场战略
  • 公司简介
    • OpenBiome
      • 关键信息
      • 概况
      • 财务（取决于数据的可用性）
      • 产品摘要
      • 近期发展情况
    • Seres Therapeutics Inc.
    • 4D Pharma plc.
    • Locus Biosciences, Inc.
    • Enterome SA
    • Finch Therapeutics Group, Inc.
    • Intralytix, Inc.
    • Microbiotica
    • Second Genome
    • Rebiotix Inc.

第十章 ：研究过程

  • 研究过程
    • 资料探勘
    • 数据分析
    • 市场评估
    • 验证
    • 出版
  • 研究属性
  • 研究假设

Global Microbiome Therapeutics Market is valued approximately at USD 92.15 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 35.32% over the forecast period 2022-2029. Microbiome treatments aim to engineer the gut microbiome by applying native or synthetic bacteria, antibiotics, bacteriophages, and bacteriocins in additive, subtractive, or modulatory therapy. The market is expanding as a result of factors including the rise in strategic partnerships for R&D, product development, and portfolio expansion in the field of microbiome therapies. Most of the therapeutic drugs in development are still in their early stages, typically between Phase I and Phase II. Out of the 23, more than 13 medicines are being studied for GI indications, with the majority focusing on ulcerative colitis. For instance, Seres Therapeutics, Inc. disclosed SER-109 trial results from its Phase 3 ECOSPOR III study in 2021. It is planned to introduce the pipeline medicine in the first half of 2023 as an oral treatment for recurrent C. difficile infection. SER-109 is connected to a decrease in antimicrobial resistance genes as opposed to placebo. Also, a 4-year partnership for the development and discovery of microbial medicines was established in January 2022 between Hudson Institute and BiomeBank.

The demand for microbiome therapies is also rising as target diseases are becoming more prevalent. The development of microbiome research is anticipated to hunt for more effective cures for infections and other ailments, improving the results of medical therapy. Companies are bringing down the cost of their goods, increasing access to cutting-edge healthcare for a greater percentage of the population, and some countries' governing authorities are changing their strategies to support the adoption of microbiome-based treatments. As a result, this offers market vendors lucrative growth opportunities to increase their market share. The high cost of microbiome treatments and strict regulatory rules brought on by the product's complexity are the two main issues limiting the market's expansion.

The key regions considered for the Global Microbiome Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. With the biggest market share in 2021, North America dominated the industry. The region's dominance is mostly due to its well-established research capabilities for the creation of innovative treatments and its expanding target population. Also, the ubiquity of initiatives like the Canadian Microbiome Initiative (CMI) in Canada makes it easier to work with partners and stakeholders. This makes it possible to concentrate research efforts on the creation of microbial medicines. For instance, the Biocodex Microbiota Foundation published a call for submissions in July 2021 for microbiome research funding totaling more than USD 26,000 in Canada. These incentives are anticipated to stimulate new market innovations. Asia Pacific is predicted to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • OpenBiome
  • Seres Therapeutics Inc.
  • 4D Pharma plc.
  • Locus Biosciences, Inc.
  • Enterome SA
  • Finch Therapeutics Group, Inc.
  • Intralytix, Inc.
  • Microbiotica
  • Second Genome
  • Rebiotix Inc.

Recent Developments in the Market:

  • In December 2021, Kaleido Biosciences and Janssen have joined forces to explore the possibility of microbiome metabolic medicines for the treatment of immunological, atopic, and metabolic diseases that first appear in childhood.
  • in July 2021, The Biocodex Microbiota Foundation published a request for submissions for microbiome research funding totalling more than USD 26,000 in Canada. These incentives are anticipated to stimulate new market innovations.

Global Microbiome Therapeutics Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Application, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Type:

  • FMT
  • Microbiome Drugs

By Application:

  • C. difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Microbiome Therapeutics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Microbiome Therapeutics Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Microbiome Therapeutics Market, by Application, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Microbiome Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Microbiome Therapeutics Market Dynamics

  • 3.1. Microbiome Therapeutics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing number of strategic collaborations for microbiome therapeutics for R&D
      • 3.1.1.2. Increase in the prevalence of target diseases.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Microbiome Therapeutics
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in Formulation

Chapter 4. Global Microbiome Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Microbiome Therapeutics Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Microbiome Therapeutics Market by Type, Performance - Potential Analysis
  • 6.3. Global Microbiome Therapeutics Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Microbiome Therapeutics Market, Sub Segment Analysis
    • 6.4.1. FMT
    • 6.4.2. Microbiome Drugs

Chapter 7. Global Microbiome Therapeutics Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Microbiome Therapeutics Market by Application, Performance - Potential Analysis
  • 7.3. Global Microbiome Therapeutics Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
  • 7.4. Microbiome Therapeutics Market, Sub Segment Analysis
    • 7.4.1. C. difficile
    • 7.4.2. Crohn's Disease
    • 7.4.3. Inflammatory Bowel Disease
    • 7.4.4. Diabetes
    • 7.4.5. Others

Chapter 8. Global Microbiome Therapeutics Market, Regional Analysis

  • 8.1. Microbiome Therapeutics Market, Regional Market Snapshot
  • 8.2. North America Microbiome Therapeutics Market
    • 8.2.1. U.S. Microbiome Therapeutics Market
      • 8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Application breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Microbiome Therapeutics Market
  • 8.3. Europe Microbiome Therapeutics Market Snapshot
    • 8.3.1. U.K. Microbiome Therapeutics Market
    • 8.3.2. Germany Microbiome Therapeutics Market
    • 8.3.3. France Microbiome Therapeutics Market
    • 8.3.4. Spain Microbiome Therapeutics Market
    • 8.3.5. Italy Microbiome Therapeutics Market
    • 8.3.6. Rest of Europe Microbiome Therapeutics Market
  • 8.4. Asia-Pacific Microbiome Therapeutics Market Snapshot
    • 8.4.1. China Microbiome Therapeutics Market
    • 8.4.2. India Microbiome Therapeutics Market
    • 8.4.3. Japan Microbiome Therapeutics Market
    • 8.4.4. Australia Microbiome Therapeutics Market
    • 8.4.5. South Korea Microbiome Therapeutics Market
    • 8.4.6. Rest of Asia Pacific Microbiome Therapeutics Market
  • 8.5. Latin America Microbiome Therapeutics Market Snapshot
    • 8.5.1. Brazil Microbiome Therapeutics Market
    • 8.5.2. Mexico Microbiome Therapeutics Market
  • 8.6. Rest of The World Microbiome Therapeutics Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. OpenBiome
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Seres Therapeutics Inc.
    • 9.2.3. 4D Pharma plc.
    • 9.2.4. Locus Biosciences, Inc.
    • 9.2.5. Enterome SA
    • 9.2.6. Finch Therapeutics Group, Inc.
    • 9.2.7. Intralytix, Inc.
    • 9.2.8. Microbiotica
    • 9.2.9. Second Genome
    • 9.2.10. Rebiotix Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Microbiome Therapeutics Market, report scope
  • TABLE 2. Global Microbiome Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Microbiome Therapeutics Market estimates & forecasts by Type 2019-2029 (USD Billion)
  • TABLE 4. Global Microbiome Therapeutics Market estimates & forecasts by Application 2019-2029 (USD Billion)
  • TABLE 5. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Microbiome Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Microbiome Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Microbiome Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Microbiome Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Microbiome Therapeutics Market
  • TABLE 70. List of primary sources, used in the study of global Microbiome Therapeutics Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Microbiome Therapeutics Market, research methodology
  • FIG 2. Global Microbiome Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Microbiome Therapeutics Market, key trends 2021
  • FIG 5. Global Microbiome Therapeutics Market, growth prospects 2022-2029
  • FIG 6. Global Microbiome Therapeutics Market, porters 5 force model
  • FIG 7. Global Microbiome Therapeutics Market, pest analysis
  • FIG 8. Global Microbiome Therapeutics Market, value chain analysis
  • FIG 9. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Microbiome Therapeutics Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Microbiome Therapeutics Market, regional snapshot 2019 & 2029
  • FIG 15. North America Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Microbiome Therapeutics Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Microbiome Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable